WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000027850) CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/027850    International Application No.:    PCT/US1999/026984
Publication Date: 18.05.2000 International Filing Date: 12.11.1999
Chapter 2 Demand Filed:    09.06.2000    
IPC:
C07D 471/16 (2006.01), C07D 487/16 (2006.01)
Applicants: NEUROCRINE BIOSCIENCES, INC. [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US) (For All Designated States Except US).
HADDACH, Mustapha [MA/US]; (US) (For US Only).
GUO, Zhiqiang [CN/US]; (US) (For US Only).
MCCARTHY, James, R. [US/US]; (US) (For US Only)
Inventors: HADDACH, Mustapha; (US).
GUO, Zhiqiang; (US).
MCCARTHY, James, R.; (US)
Agent: HERMANNS, Karl, R.; SEED and BERRY LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
GOWSHALL, Jonathan, V.; Forrester & Boehmert, Fran-Joseph-Strasse 38, D-80801 München (DE)
Priority Data:
09/190,958 12.11.1998 US
09/400,744 21.09.1999 US
Title (EN) CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
(FR) ANTAGONISTES DE RECEPTEURS DU CRF ET METHODES ASSOCIEES
Abstract: front page image
(EN)Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in warmblooded animals, including stroke. The compounds of this invention have structures (I): (a) wherein $i(n), $i(m), R, R¿1?, R¿2?, X and Ar are as defined herein, including stereoisomes and pharmaceutically acceptable salts thereof.
(FR)L'invention concerne des composés qui sont utiles dans le traitement de diverses affections, notamment dans le traitement d'affections dans lesquelles on observe une hypersécrétion de CRF chez les animaux à sang chaud, en particulier les accidents vasculaires cérébraux. Les composés de l'invention présentent la structure de la formule (I), dans laquelle $i(n), $i(m), R, R¿1?, R¿2?, X et Ar sont tels que définis dans le descriptif, y compris leurs stéréoisomères et leurs sels acceptables sur le plan pharmaceutique.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)